Samlyn Capital, LLC Biomarin Pharmaceutical Inc Transaction History

Samlyn Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $41.5 Million - $64.7 Million	-521,079 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $11 Million - $14.9 Million	-154,291 Reduced 22.85%	521,079 $44 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $11.5 Million - $15.4 Million	178,320 Added 35.88%	675,370 $57.1 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $33.5 Million - $42.3 Million	497,050 New	497,050 $33.5 Million

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Samlyn Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Samlyn Capital, LLC with notifications on news.